We are delighted to announce the programme for our one-day, in person event, celebrating the 70th anniversary of the British Society for Immunology. This will feature invited speakers, poster presentations and industry support.

📆Monday 27th April 2026

📍Great Hall, Queen’s University Belfast

Cytokine multimerization: when more is more and sometimes less Nature Reviews Immunology, Published online: 08 April 2026; doi:10.1038/s41577-026-01290-6This Review discusses how cytokine multimerization affects the engagement of cytokines with their receptors and their biological activity. The authors explain the relevance of cytokine multimerization in disease settings and the implications for cytokine-targeting therapies.

Cytokine multimerization: when more is more and sometimes less

Tofacitinib improved a range of patient-reported outcomes in patients with #JIA @cincyresearch.bsky.social acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

JAK inhibitors: risks and safety principles Introduction The Janus kinases (JAKs) are protein tyrosine kinases that mediate cellular responses to several cytokines and growth factors, which play a role in immune defence and immune-mediated…

*JAK inhibitors: risks and safety principles*

An overview of the mechanism of action of JAK inhibitors, as well as the risks and common side effects of their use in treating chronic inflammatory disorders

#JAKinhibitors #inflammatorydisorders

@biorxivpreprint.bsky.social Selective JAK Inhibition Reveals Paradoxical and Hierarchical Control of IFN-γ-driven Autoimmunity in AIRE Deficiency
www.biorxiv.org/content/10.6... @niaidnews.bsky.social

Fantastic @bonellilab.bsky.social !!

JAMA Oncology "Research Letter" titled "Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial" by Chengshui Chen, MD, PhD1; Xinyu Liang, MD1; Zheng Peng, MD1; et al. Published Online: March 5, 2026.

Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events.

ja.ma/3MVSbwT

Common γ-chain cytokines induce an epigenomically plastic precursor-like KIT+ ILC2 state linked to immune disease susceptibility www.biorxiv.org/content/10.64898/2026.02...

The Ulster Immunology Group is delighted to host a one-day, in-person event to celebrate the 70th anniversary of the British Society for Immunology, bringing together researchers, clinicians and students from across Ulster.

📆Monday 27th April

📍Great Hall, Queen’s University Belfast

Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications - Nature Reviews Drug Discovery The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway mediates cellular responses to cytokines and growth factors, and its dysregulation plays a role in various disord...

The JAK–STAT pathway is an important target for drugs for inflammatory and autoimmune disorders. This Review discusses recent advances in JAK and STAT inhibitor development and highlights emerging therapeutic indications nature.com/articles/s41... rdcu.be/eXDui

"Tofacitinib reduced the IFN signature, and survival in this group did not differ significantly from healthy controls, whereas untreated- and baricitinib-treated HT mice showed shorter survival".
This is SO interesting. Why is tofa better than bari ? Why are IFN scores lower in tofa-treated mice?

This is a really interesting study. Worth thinking at a very similar approach for other pathologies for which JAKinibs are a proved therapeutic possibility (RA, SpA, JIA etc.)
#ImmunoSky #Immunology #JAKinibs #JAKi
www.jaad.org/article/S019...

Congratulations to Mariana and Mike! This story is finally out!

Acne Risk When Treating Atopic Dermatitis With JAK Inhibitors This cohort study evaluates the risk of acne in adult patients with atopic dermatitis who started treatment with Janus kinase inhibitors compared with Th2 cytokine inhibitors.

Increased risk of acne in patients with atopic dermatitis treated with JAK inhibitors. Interesting, risks increased if patients were previously treated with a biologic such as dupilumab.
#JAK #JAKinibs #ImmunoSky #Immunology
jamanetwork.com/journals/jam...

Review @natrevimmunol.nature.com
Inflame and restrain — the paradoxical roles of IL-12 and IL-23 in immunity
www.nature.com/articles/s41...

#Pharmacological Characterization of #Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor
Mehrotra et al
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch

As my month-long sabbatical at Sapienza University in Rome comes to an end, I was happy to speak again to third year medical students about cytokine signaling and JAKinibs. I was expecting more people with ugly sweaters though ... 😤 😂
Thank you @pikolab.bsky.social

A report by Muhammad Junejo et al., "JAK1 Inhibition is Sufficient for the Treatment of Granuloma Annulare" https://doi.org/10.1016/j.jid.2025.04.030 #JIDJournal #DermatologyJournal #dermatology #dermatologists #dermresearch #dermscience #dermsky

Laboratory “classic” Christmas tree 😅
#ImmunoSky #research #cytometry

Non scientific post… but I just witness the Olympic torch pass in front of me in Roma (on its way to Milano Cortina winter games.
How lucky #Olympicgames
#torch

What an honor to be able to present our work at Università Sapienza in Rome today hosted by @sciumelab.bsky.social, while I am here for an month as visiting professor. Amazing experience!
#JAKinibs #Cytokines #ImmunoSky

Not surprised of unexpected positive effects of JAKinibs
#JAK #JAKinibs #ImmunoSky

NIH Job Postings Raise Red Flags for Scientists A dozen high-level spots are open for a short period of time

Yup! This is what is going on at NIH...
www.medpagetoday.com/washington-w...

JAKs, STATs, and New Targets in Inflammatory Skin Disease | Dermatology Times Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

My comments recorded at ISDS 2025 last week in NYC.
#dermatology #jakinibs #inflammation #ImmunoSky

www.dermatologytimes.com/view/jaks-st...

New review out! 😊 20 years after it’s discovery, with @iannaconelab.bsky.social we decided to bring together what we currently know about this cytokine and how it shapes CD8 T cell responses. A small contribution to make sense of a field that is moving fast 🌈 @cp-trendsimmuno.bsky.social

Excited to be a speaker at ISDS 2025. A truly fantastic conference #ImmunoSky
#Jakinibs

🚨Thrilled to share our latest work, published online today
@nature.com in which we decipher mechanisms underlying the enigmatic VEXAS syndrome - a huge team effort
@mskcancercenter.bsky.social led by superstars Varun Narendra + @tandriladas.bsky.social 1/

www.nature.com/articles/s41...

#Medsky🧪 #IDSky #oncosky #immunosky #pharmsky #publichealth #Ruxolitinib has shown promise for treating some symptoms of #LongCOVID by targeting the persistent, low-grade inflammation that characterizes the condition. As a Janus kinase (JAK) inhibitor,

@biorxivpreprint.bsky.social IL-36 upregulates type-I IFN responses in systemic #lupus erythematosus by promoting the accumulation of self-nucleic acids
www.biorxiv.org/content/10.1... @kingscollegelondon.bsky.social

Friday Night in San Francisco.
Al Di Meola, John McLaughlin, Paco de Lucia